These are the stocks posting the largest moves before the bell.Market Insiderread more
Mnuchin tells CNBC he's confident President Trump and China's Xi Jinping can make progress in stalled trade talks.World Economyread more
U.S. stock index futures jumped Wednesday morning after Treasury Secretary Steven Mnuchin told CNBC that the U.S. and China were close to reaching a trade deal.US Marketsread more
JP Morgan's Jamie Dimon says student lending "is a disgrace and its hurting America," he told Yahoo Finance Tuesday.Economyread more
Trump is willing to talk with Iran, but he's "also determined to enforce the U.S. and our allies' interests in the region," Mnuchin tells CNBC.Politicsread more
Democrats want Mueller's testimony on his probe into Russian interference in the 2016 election and Trump's efforts to influence it.Politicsread more
Mortgage application volume was 40% higher than a year ago, largely because lower rates are strengthening the refinance market.Real Estateread more
Stocks should rally if the U.S. and China agree to new negotiations and a ceasefire in the trade war, but the economic impact of tariffs will continue.Market Insiderread more
Bitcoin surged as high as $12,919 in early morning trade Wednesday, to its highest level since January 2018.Technologyread more
AbbVie's deal to buy Allergan for about $63 billion is a "nice exit from a tough situation," RBC Capital Markets analyst Randall Stanicky says.Biotech and Pharmaceuticalsread more
Omada Health just raised $73 million at a valuation of around $600 million as it seeks to expand its digital health offerings.Technologyread more
In the race to stop the Ebola virus in its tracks, a vaccine that would help prevent people from contracting the deadly disease would be a powerful weapon.
Yet a vaccine still seems far off, even though global health officials are urging countries and companies to fast-track efforts to develop one, without compromising safety and effectiveness.
And there's the rub. Safe and effective vaccines are difficult and expensive to develop in the best of times. That process is more difficult in the midst of a growing health crisis.
Even the medicines being tested to treat a patient already diagnosed with Ebola offer no easy solutions.
Thomas Eric Duncan, the Liberian man who is undergoing treatment for Ebola and listed in serious condition in Dallas, won't be getting the experimental drug ZMapp used on several international aid workers and medical staff, including at least two other Americans.
That's because the company that makes ZMapp, Mapp Biopharmaceutical, has run out of supplies.
That's prompted U.S. government officials to try and ramp up production of ZMapp through a small biotech company in Texas.
All this just highlights how difficult it is to create new medicines to stop deadly threats like Ebola, said Dr. Pascal James Imperato, dean of the School of Public Health at SUNY Downstate Medical Center.
"It would be great to have a vaccine but it takes time to develop these treatments and there are the technical hurdles like testing to go through, " Imperato said. "It's just not that easy to make them."
Imperato added that even coming up with a vaccine may not do the trick. That's because Ebola has so many mutating strains, making it much more difficult to find one drug that fits all.
The fact that Duncan's case—the first diagnosis of Ebola in the U.S.—has received so much attention, could put more pressure on finding a vaccine and might do more harm than good, said Dr. Robert Quigley, U.S. medical director and senior vice president of medical assistance for International SOS.
"We have to make sure a vaccine works," Quigley said. "The side effects could be more harmful than realized."
One Canadian firm, Tekmira, is also working on a treatment, with funds from the U.S Defense Department.
Most of the larger outfits have shied away because of the expense and time involved in getting a vaccine on the market.
"It's tough to develop these drugs because they might not even be used," said Dr. Chris Milne, director of research at the Tufts Center for the Study of Drug Development.
Milne said that pharmaceutical companies can spend millions in developing vaccines like for the flu, that get thrown away because they're ineffective on new virus strains.
"It's a lot of time, effort and money to develop something like an Ebola vaccine with little guarantee of a profit," he said.
And Milne said it can take up to eight to 10 years before a proven vaccine can reach patients, so no vaccine seems readily available.
But GlaxoSmithKline and the National Institutes of Health have recently partnered on an Ebola vaccine that has entered Phase 1 clinical trials.
"We got approval to get the process going within 48 hours from the Federal Drug Administration when it normally takes 30 days," said Dr. David Vaughn, head of GlaxoSmithKline's external research and development, North America.
Vaughn said the the vaccine was first developed at the European company Okarios, which Glaxco bought in 2013. Vaughn couldn't say when the vaccine might be available for general use but said that GlaxoSmithKline is "going as quickly as we can without compromising the safety" of the vaccine.
As for ZMapp, the jury is still out on it's effectiveness. A doctor in the West African nation of Liberia who had Ebola died despite taking it.
"It's too early to say if ZMapp worked or not," said SUNY's Imperato. "The patients who got it and survived underwent other treatment and that may have helped them just as much as the drug."
Ebola is believed to have sickened more than 6,500 people in West Africa, and over 3,000 people have died.
That's spurred calls for global action. The World Health Organization (WHO) is urging international efforts to develop an Ebola vaccine "within a matter of months ... without compromising international standards for safety and efficacy. "
In the U.S., President Barack Obama on Tuesday discussed "stringent isolation protocols" with the head of the Centers for Disease Control (CDC) to limit the risk of more Ebola cases after the diagnosis in Dallas.
The United States is deploying 3,000 soldiers to build treatment center and train local medics in West Africa. Other nations, including Britain, France, China and Cuba, have pledged military and civilian personnel alongside cash and medical supplies.
Even before Duncan was diagnosed with Ebola, some pharmaceutical firms said they were accelerating testing efforts to come up with a vaccine.
Meanwhile, the WHO has said the total number of infections could reach 20,000 by November, months earlier than previously forecast.
The CDC recently warned between 550,000 and 1.4 million people might be infected in West Africa by January if nothing is done.
But even if a vaccine is available, it's not for everyone, said International SOS' Quigley.
"It's not like getting a flu shot," he said. "It should only be available for those at risk, like health-care workers and those who live and are traveling in the areas of outbreak."
UPDATED: This story was updated to include the ZMapp production schedule, a statement from the World Health Organization and comments from a doctor at GlaxoSmithKline.